Table 1.

Overview of clinical study cohorts evaluating pre-treatment circulating type III collagen pro-peptides as non-invasive measures of tumor fibrosis and their association with overall survival (OS)

Study	Cancer type	Therapy	No. of pts	Sample source	Cut-off	HR for OS	95% CI	p value
Lipton et al. [119]	Breast cancer, metastatic, ER/PR +	Letrozole	148	Serum	29.5 ng/ml	1.95	1.22–3.09	0.005
Lipton et al. [119]	Breast cancer, metastatic, HER2 +	Trastuzumab	55	Serum	25.5 ng/ml	3.37	1.67–6.80	0.001
Willumsen et al. [120]	Pancreatic cancer, advanced	Chemotherapy (5-FU)	176	Serum	10.4 ng/ml	2.01	1.33–3.05	0.001
Chen et al. [38]	Pancreatic cancer, all stages	Chemotherapy (SoC)	809	Serum	100 ng/ml increase	1.28	1.11–1.49	< 0.01
Jensen et al. [121]	Melanoma, metastatic	Ipilimumab	66	Serum	19.6 ng/ml	2.13	1.12–4.04	0.021
Hurkmans et al. [122]	Melanoma, metastatic	Nivolumab or Pembrolimumab	107	Serum	12.6 ng/ml	2.41	1.26–4.60	0.008
Jensen et al. [36]	Liver cancer, all stages	Various	79	EDTA plasma	23.9 ng/ml	2.12	1.10–4.05	0.024
Nissen et al. [123]	Colorectal cancer, metastatic	Chemotherapy + Bevacizumab	252	Serum	13.2 ng/ml	2.01	1.54–2.64	< 0.0001

ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, 5-FU 5-Fluorouracil, SoC standard of care, HR hazard ratio, CI confidence intervals